<DOC>
	<DOCNO>NCT02719418</DOCNO>
	<brief_summary>The purpose study assess accumulation anti-Xa activity occur repeat daily administration prophylactic dos tinzaparin patient severe chronic kidney disease ( CKD ) require thromboprophylaxis non-surgical condition . It anticipate tinzaparin use fix dose thromboprophylaxis severe CKD patient ( eGFR ≤ 30 ml/min /1.73 m2 ) risk venous thromboembolism ( VTE ) bioaccumulate significant level , mean increase ≥ 20 % anti-Xa mean level day 2 3 day 5 .</brief_summary>
	<brief_title>Study Bioaccumulation Tinzaparin Renally Impaired Patients When Given Prophylactic Doses</brief_title>
	<detailed_description>STUDY DESIGN : Prospective , monocentric , open-label , single-arm , observational cohort study Subjects hospitalize non-surgical reason medical department ( ie Nephrology , Pneumology , Cardiology Internal medicine ) chronic kidney disease ( baseline eGFR ≤30 ml/min/1.73 m2 ) receive tinzaparin prophylaxis dose 3500 IU ( 4500 IU BMI &gt; 30kg/m2 ) once-daily . Pharmacokinetic parameter : Peak anti-Xa analysis do 2 ( 3 ) , 5 , 8 day treatment , one trough anti-Xa analysis day 5 . The bioaccumulation tinzaparin assess determine whether dose regimen associate excessive increase anti-Xa level course treatment ( see statistical analysis ) . RECRUITMENT PROCESS : A systematic screening potential study subject make research coordinator base key computer search field throughout four different software . Through database , researcher able perform preliminary selection eligible subject identify hospitalized patient ultimately treat . The pharmacist responsible validation tinzaparin prescription pharmacy department work research team initial screen identify eligible candidate . Since choice prescribe agent prescriber 's discretion , recruitment procedure trigger mainly soon prescription tinzaparin thromboprophylaxic dose written.Subjects meet inclusion criterion meet exclusion criterion consider eligible candidate additional baseline information collect point , ethnicity sex . The eligible participant address directly member research team . Informed consent seek document Information Form Informed Consent ( FIC ) already approve ethic committee hospital . DATA COLLECTION : Four blood sample , three collect 4±1 hour injection tinzaparin day 2 ( 3 ) , day 5 day 8 , one trough collect day 5 . Pre-identified tube ( encode ) provide nursing sample shipping staff specific instruction manipulation blood sample ship laboratory . STUDY SAMPLE : In study , consider bioaccumulation statistically significant Cmax anti-Xa increase least 20 % . Estimation population size perform use information obtain Mahé et al . due similar nature population study . As mean plasma anti-Xa peak level , study do Bara L et al . show 431 patient receive 3 500 IU tinzaparin thromboprophylaxis mean 0.15 IU/ml , dose give subject present study . Based coefficient variation Mahé et al . 0.36 mean plasma anti-Xa level find Bara L. et al , standard deviation 0.05 IU/ml establish , consider coefficient variation maintain across dose administer . For purpose study , researcher presume identical variance anti-Xa level regardless day blood sample collection . According null hypothesis , mean distribution 0.15 IU/ml alternative hypothesis ; average would 0.18 IU/ml ( since establish cut-off 20 % increase ) . With paired one-tailed test , alpha error 0.05 , power 0.90 , strong correlation measurement ( r=0.7 ) , 25 participant require detect increase ≥ 20 % anti-Xa activity sample day 2 3 maximum 8 day .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Tinzaparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Age ≥ 18 year old A prescription prophylactic tinzaparin ( 3500 IU 4500 IU ) initiate order treat physician Patient admit medical reason one ( limit ) follow ward : nephrology , internal medicine , cardiology pneumology Chronic severe renal impairment define eGFR ≤ 30 mL/min/1.73 m2 moment prescription available , eGFR baseline , ie ≤ 30 ml/min/1.73 m2 last 3 month Estimated length stay ≥ 5 day Written inform consent obtain within 3 ± 1 hour second third dose tinzaparin . Super obese ( Bodymass Index ( BMI ) &gt; 50kg/m2 ) Treatment UFH , LMWH oral factor Xa inhibitor &lt; 48h prior start first dose tinzaparin Prophylaxis LMWH tinzaparin &lt; 48h prior start first dose tinzaparin Prophylaxis heparin &lt; 12h prior start first dose tinzaparin Treatment argatroban , bivalirudin &lt; 24 hour prior start first dose tinzaparin Treatment oral direct thrombin inhibitor , danaparoid , fondaparinux , antivitamin K agent &lt; 7 day prior start first dose tinzaparin Acute renal failure individual baseline eGFR &gt; 30 ml/min/1.73 m2 Prophylactic tinzaparin use 72h inclusion Severe liver insufficiency ( Child Pugh C ) Anuria chronically dialyse patient ( eGFR &lt; 5 ml/min/1.73 m2 ) Participation another study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Thromboembolism</keyword>
	<keyword>Venous Thrombosis</keyword>
	<keyword>Embolism Thrombosis</keyword>
	<keyword>Chronic Renal Diseases</keyword>
	<keyword>Kidney Failure , Chronic</keyword>
	<keyword>Renal Failure , Chronic</keyword>
	<keyword>Venous Thromboembolism</keyword>
	<keyword>Tinzaparin</keyword>
	<keyword>Innohep</keyword>
	<keyword>Heparin , Low-Molecular-Weight</keyword>
</DOC>